MX2015008293A - Derivados de pirimidona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral. - Google Patents

Derivados de pirimidona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral.

Info

Publication number
MX2015008293A
MX2015008293A MX2015008293A MX2015008293A MX2015008293A MX 2015008293 A MX2015008293 A MX 2015008293A MX 2015008293 A MX2015008293 A MX 2015008293A MX 2015008293 A MX2015008293 A MX 2015008293A MX 2015008293 A MX2015008293 A MX 2015008293A
Authority
MX
Mexico
Prior art keywords
viral disease
amelioration
prevention
treatment
pyrimidone derivatives
Prior art date
Application number
MX2015008293A
Other languages
English (en)
Inventor
Helmut Buschmann
Sung-Sau So
Zhuming Zhang
Achyutharao Sidduri
Andrea Wolkerstorfer
Oliver Szolar
Stephen Cusack
Mark Smith
Norbert Handler
Ronald Charles Hawley
Original Assignee
Savira Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50070507&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015008293(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Savira Pharmaceuticals Gmbh filed Critical Savira Pharmaceuticals Gmbh
Publication of MX2015008293A publication Critical patent/MX2015008293A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención hace referencia a un compuesto que tiene la fórmula general (I), opcionalmente en la forma de una sal, solvato, polimorfo, profármaco, cofármaco, cocristal, tautómero, racemato, enantiómero o diastereómero farmacéuticamente aceptable o sus mezclas, (ver Fórmula) que son útiles en el tratamiento, la mejora o preveción de una enfermedad viral. Además, se describen tratamientos de combinación específicos.
MX2015008293A 2013-01-08 2014-01-07 Derivados de pirimidona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral. MX2015008293A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361750017P 2013-01-08 2013-01-08
PCT/EP2014/050165 WO2014108406A1 (en) 2013-01-08 2014-01-07 Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease

Publications (1)

Publication Number Publication Date
MX2015008293A true MX2015008293A (es) 2016-06-02

Family

ID=50070507

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015008293A MX2015008293A (es) 2013-01-08 2014-01-07 Derivados de pirimidona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral.

Country Status (21)

Country Link
US (1) US9045486B2 (es)
EP (1) EP2943495B1 (es)
JP (1) JP2016518305A (es)
KR (1) KR20150103285A (es)
CN (1) CN104918942A (es)
AR (1) AR094378A1 (es)
AU (1) AU2014204889A1 (es)
BR (1) BR112015012693A2 (es)
CA (1) CA2894642A1 (es)
CL (1) CL2015001916A1 (es)
CR (1) CR20150337A (es)
EA (1) EA201591291A1 (es)
HK (2) HK1211286A1 (es)
IL (1) IL239656A0 (es)
MA (1) MA38323B1 (es)
MX (1) MX2015008293A (es)
PE (1) PE20151722A1 (es)
PH (1) PH12015501517A1 (es)
SG (1) SG11201503946UA (es)
TW (1) TW201443053A (es)
WO (1) WO2014108406A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201300304D0 (en) 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
IL239682B (en) 2013-01-08 2018-10-31 Kalvista Pharmaceuticals Ltd History of benzylamine and 2-(aminomethyl)pyridine
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
UA121199C2 (uk) 2013-09-12 2020-04-27 Аліос Біофарма, Інк. Азапіридонові сполуки та їх застосування
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
EA036776B1 (ru) 2015-03-11 2020-12-21 Янссен Байофарма, Инк. Соединения азапиридона и способы их применения
MX2021006404A (es) 2015-04-28 2022-08-02 Shionogi & Co Derivados de piridona policiclica sustituida y profarmaco de los mismos.
LT3428170T (lt) 2015-04-28 2021-02-10 Shionogi & Co., Ltd Policiklinis piridono darinys nuo gripo ir jo provaistas
WO2017072341A1 (en) 2015-10-30 2017-05-04 F. Hoffmann-La Roche Ag Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
SG10201911957QA (en) 2015-12-15 2020-02-27 Shionogi & Co Medicine for treating influenza characterized by comprising combination of cap-dependent endonuclease inhibitor with anti-influenza drug
WO2017109088A1 (en) 2015-12-23 2017-06-29 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
EP3426656B1 (en) * 2016-03-08 2021-05-12 Novartis AG Tricyclic compounds useful to treat orthomyxovirus infections
WO2017158151A1 (en) 2016-03-18 2017-09-21 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
WO2017158147A1 (en) 2016-03-18 2017-09-21 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
JP6961963B2 (ja) * 2016-04-01 2021-11-05 三菱ケミカル株式会社 フルフラールの製造方法
CN109153682B (zh) * 2016-05-20 2021-05-25 豪夫迈·罗氏有限公司 用于治疗感染性疾病的具有氧、硫和氮连接基的新的吡嗪化合物
PL3464271T3 (pl) 2016-05-31 2021-01-25 Kalvista Pharmaceuticals Limited Pochodne pirazolowe jako inhibitory kalikreiny osoczowej
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
SG10201912212XA (en) 2016-08-10 2020-02-27 Shionogi & Co Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof
JOP20170169A1 (ar) 2016-08-29 2019-01-30 Novartis Ag مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو
HUE057912T2 (hu) 2017-11-29 2022-06-28 Kalvista Pharmaceuticals Ltd Plazma kallikrein inhibitort tartalmazó dózisformák
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
SG11202007718SA (en) 2018-02-28 2020-09-29 Novartis Ag 10-(di(phenyl)methyl)-4-hydroxy-8,9,9a,10-tetrahydro-7h-pyrrolo[1 ',2':4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza
EP4010333A1 (en) 2019-08-09 2022-06-15 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
JP2023519870A (ja) * 2020-03-25 2023-05-15 エスアールアイ インターナショナル インフルエンザウイルスエンドヌクレアーゼの三環式阻害剤
EP4074317A1 (en) 2021-04-14 2022-10-19 Bayer AG Phosphorus derivatives as novel sos1 inhibitors
WO2024061300A1 (en) * 2022-09-22 2024-03-28 Insilico Medicine Ip Limited Inhibitors of trex1 and uses thereof
WO2024083933A1 (en) 2022-10-19 2024-04-25 Astrazeneca Ab 2,4,6-trisubstituted 1,3,5-triazines as modulators of cx 3cr1

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5475109A (en) 1994-10-17 1995-12-12 Merck & Co., Inc. Dioxobutanoic acid derivatives as inhibitors of influenza endonuclease
CA2557926A1 (en) * 2004-03-09 2005-09-22 Monica Donghi Hiv integrase inhibitors
WO2006030807A1 (ja) 2004-09-15 2006-03-23 Shionogi & Co., Ltd. Ｈｉｖインテグラーゼ阻害活性を有するカルバモイルピリドン誘導体
TW200716632A (en) 2005-05-16 2007-05-01 Gilead Sciences Inc Integrase inhibitor compounds
AU2006272521A1 (en) * 2005-07-27 2007-02-01 Gilead Sciences, Inc. Antiviral phosphonate conjugates for inhibition of HIV
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
JP5697163B2 (ja) 2009-03-26 2015-04-08 塩野義製薬株式会社 置換された３−ヒドロキシ−４−ピリドン誘導体
EP2444400B1 (en) 2009-06-15 2018-03-28 Shionogi&Co., Ltd. Substituted polycyclic carbamoylpyridone derivative
WO2011000566A2 (en) 2009-06-30 2011-01-06 Savira Pharmaceuticals Gmbh Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections
RS57490B1 (sr) * 2010-09-24 2018-10-31 Shionogi & Co Supstituisani prolek derivata policikličnog karbamoil piridona

Also Published As

Publication number Publication date
JP2016518305A (ja) 2016-06-23
AR094378A1 (es) 2015-07-29
AU2014204889A1 (en) 2015-06-11
PE20151722A1 (es) 2015-11-19
KR20150103285A (ko) 2015-09-09
HK1211286A1 (en) 2016-05-20
HK1212686A1 (zh) 2016-06-17
CL2015001916A1 (es) 2016-01-22
MA38323A1 (fr) 2017-02-28
PH12015501517A1 (en) 2015-11-09
US9045486B2 (en) 2015-06-02
TW201443053A (zh) 2014-11-16
MA38323B1 (fr) 2018-05-31
US20140194431A1 (en) 2014-07-10
CN104918942A (zh) 2015-09-16
SG11201503946UA (en) 2015-09-29
CR20150337A (es) 2015-11-02
EP2943495B1 (en) 2016-12-28
CA2894642A1 (en) 2014-07-17
BR112015012693A2 (pt) 2017-07-11
EP2943495A1 (en) 2015-11-18
EA201591291A1 (ru) 2015-12-30
IL239656A0 (en) 2015-08-31
WO2014108406A1 (en) 2014-07-17

Similar Documents

Publication Publication Date Title
PH12015501517A1 (en) Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
MX2014014106A (es) Derivados de acido 7-oxo-tiazolopiridinocarbonico y su uso en el tratamiento, disminucion o prevencion de una enfermedad viral.
MX2014014109A (es) Derivados de 7-oxo-4,7-dihidro-pirazolo[1,5-a]pirimidina que son utiles en el tratamiento, mejora o prevencion de una enfermedad viral.
PH12019500163A1 (en) Tetrahydro- and dihydro-isoquinoline prmt5 inhibitors and uses thereof
MX2014003801A (es) Derivados de pirimidin-4-ona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral.
MX2015008288A (es) Derivados de piridona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral.
PH12017500276A1 (en) Aminopyrimidinyl compounds as jak inhibitors
MY202022A (en) Pyrrolotriazine compounds as tam inhibitors
EA033689B9 (ru) Ингибиторы g12c kras
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
PH12019500480A1 (en) Pyridine compound
PH12018500360A1 (en) Heteroaryl derivatives as parp inhibitors
WO2015200481A8 (en) Mnk inhibitors and methods related thereto
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
MX2014003803A (es) Derivados de acido heteroarilo hidroxamico y su uso en el tratamiento, mejora o prevencion de una enfermedad viral.
EA033544B1 (ru) Производные пиридона в качестве ингибиторов киназы, реаранжированной во время трансфекции (ret)
MX2015011245A (es) Un inhibidor de mdm2 derivado de acido benzoico para el tratamiento del cancer.
MX2021005207A (es) Formulaciones de 2-(terc-butilamino)-4-((1r,3r,4r)-3-hidroxi-4-met ilciclohexilamino)-pirimidina-5-carboxamida.
MX2013012588A (es) Inhibidores de cinasa.
IN2015MN00002A (es)
MX2017000208A (es) Derivados de quinolizinona como inhibidores de pi3k.
EA201692298A1 (ru) Производные карбоксамидов
MX2015008292A (es) Derivados de naftiridinona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral.
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
IN2015MN00045A (es)